In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
about
Control of RANKL gene expressionControl of bone mass and remodeling by PTH receptor signaling in osteocytesBone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patientsBone mineral density in pseudohypoparathyroidism type 1a.The changing face of hypophosphatemic disorders in the FGF-23 erac-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism.Effects of eldecalcitol on cortical bone response to mechanical loading in ratsA finer tuning of G-protein signaling through regulated control of RGS proteins.D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management.Osteocyte RANKL: new insights into the control of bone remodelingThe role of the immune system in the pathophysiology of osteoporosis.Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass.Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells.Osteocyte control of osteoclastogenesis.Role of Regulators of G Protein Signaling Proteins in Bone Physiology and Pathophysiology.Commitment to the osteoblast lineage is not required for RANKL gene expression.RANKL inhibition for the management of patients with benign metabolic bone disorders.Role of regulator of G protein signaling proteins in bone.Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.Vitamin D3 analogs for the treatment of osteoporosis.Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.Histochemical examination of the effects of high-dose 1,25(OH)2D3 on bone remodeling in young growing rats.IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
P2860
Q24619669-EF7EA5D0-A616-42A5-90A7-8E7DD1601AACQ27300741-1C8DEB63-0489-47FB-B445-F5DD7D05F406Q33765423-7755DE9B-8DEE-40F2-9B73-D0EF1CD6C421Q34113096-9C14E592-47BF-4771-858B-A190B7EDB2D9Q34221238-E47DF4F8-16FA-4C8B-BD9E-AB7A687C8677Q34264017-83807FED-DD07-41B2-B8A5-C6CA4CF17AD1Q34589725-3FAEF0CD-1451-414E-AF5A-14FA13E9B7BFQ35677911-11356A7B-4EC8-4537-A01B-E2E9A3C907DAQ36115328-00FB01E0-6564-468A-800E-3E7CAAB887F2Q36174291-C1A1540B-9220-4397-B0C7-4FF0D597D79DQ36253514-9EACD577-0C61-4CEE-837E-5E529FF57D76Q36324969-3A191958-5E4F-409C-94A8-B2BA7AFD20A4Q36372606-C23BE5F6-A112-43E8-A212-1C84CA641DD5Q36504284-B0FE5D2D-3CA7-467B-BA3B-475D09AF9CCAQ36514172-10E9E47A-D77C-418D-9E39-FE699F640348Q36756644-EFEB5015-8AEC-4E6E-8D0E-E30F93101329Q37176364-0ED7F1E6-1C90-4931-93AD-506346652708Q37532561-63806175-F89D-4563-950C-D7DF03469E6BQ37665104-6BDFB469-1C37-4C24-BB30-729A26F1C733Q38087995-1257CA00-11EE-417D-A494-C7BC9138C0E2Q38411546-F3DC412D-B6DF-4C9B-B022-9A141312AB7FQ46389765-A1D6E322-CA1A-473D-96FF-3ED9053E5AC0Q50507283-343E06CC-2FC0-47AD-B3F4-50DEF6EB8445Q53670887-51EA91CC-62FD-4452-A6B1-AB618451D9B5
P2860
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
In vivo administration of 1,25 ...... s constantly infused with PTH.
@en
In vivo administration of 1,25 ...... s constantly infused with PTH.
@nl
type
label
In vivo administration of 1,25 ...... s constantly infused with PTH.
@en
In vivo administration of 1,25 ...... s constantly infused with PTH.
@nl
prefLabel
In vivo administration of 1,25 ...... s constantly infused with PTH.
@en
In vivo administration of 1,25 ...... s constantly infused with PTH.
@nl
P2093
P356
P1476
In vivo administration of 1,25 ...... s constantly infused with PTH.
@en
P2093
Hisashi Murayama
Katsuyuki Fujii
Tatsuo Suda
Toshimasa Shinki
Yumiko Nagai
Yutaka Ueno
P304
P356
10.1002/JCB.10623
P577
2003-10-01T00:00:00Z